Evoq Remedies Ltd.

As of March 31, 2025, Evoq Remedies Ltd. carries a market capitalization of 63.74M, placing it among publicly traded companies globally. Its enterprise value stands at 61.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2025, Evoq Remedies Ltd. has 24.90M shares outstanding.

These figures are as of March 31, 2025.

As of March 31, 2025, Evoq Remedies Ltd. maintains a current ratio of 9.10, meaning it holds 9.1x the short-term assets needed to cover near-term liabilities.

As of the close on October 22, 2026, Evoq Remedies Ltd.'s stock has declined approximately 68.42% over the past 52 weeks. The 50-day moving average sits at 1.65, while the 200-day moving average is 2.60.

As of March 31, 2025, Evoq Remedies Ltd. holds 2.14M in cash and equivalents against - - in total debt, resulting in a net debt position of -2.14M. Total book value stands at 445.36M, with working capital of 443.13M providing operational flexibility.